Report an error

Spotted something inaccurate in “Oral TYK2/JAK1 Inhibitor Brepocitinib Achieves Skin Remission in Phase 3 Dermatomyositis Trial”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.